ATE205401T1 - Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 - Google Patents

Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Info

Publication number
ATE205401T1
ATE205401T1 AT98930578T AT98930578T ATE205401T1 AT E205401 T1 ATE205401 T1 AT E205401T1 AT 98930578 T AT98930578 T AT 98930578T AT 98930578 T AT98930578 T AT 98930578T AT E205401 T1 ATE205401 T1 AT E205401T1
Authority
AT
Austria
Prior art keywords
psoriasis
neutralizing antibodies
local treatment
biological activity
pharmaceutical composition
Prior art date
Application number
AT98930578T
Other languages
English (en)
Inventor
George Q W Ye
Original Assignee
Yes Biotech Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yes Biotech Lab Ltd filed Critical Yes Biotech Lab Ltd
Application granted granted Critical
Publication of ATE205401T1 publication Critical patent/ATE205401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98930578T 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8 ATE205401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN97112184A CN1068524C (zh) 1997-06-23 1997-06-23 一种治疗顽症牛皮癣的药物
PCT/CA1998/000604 WO1998058671A1 (en) 1997-06-23 1998-06-23 Topical treatment of psoriasis using neutralizing antibodies to il-8

Publications (1)

Publication Number Publication Date
ATE205401T1 true ATE205401T1 (de) 2001-09-15

Family

ID=5172124

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930578T ATE205401T1 (de) 1997-06-23 1998-06-23 Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8

Country Status (9)

Country Link
US (1) US20030077283A1 (de)
EP (1) EP0991423B1 (de)
CN (1) CN1068524C (de)
AT (1) ATE205401T1 (de)
AU (1) AU727937B2 (de)
CA (1) CA2291144C (de)
DE (1) DE69801660T2 (de)
ES (1) ES2164434T3 (de)
WO (1) WO1998058671A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379274A4 (de) * 2001-03-23 2006-02-15 Univ Texas Verfahren zur hemmung von angiogenese, tumorwachstum und metastasen mit voll humanem anti-il8 und anti-muc18 bei diversen tumortypen
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
AU2003299641C1 (en) 2002-12-16 2016-06-02 Cormorant Pharmaceuticals Ab Human monoclonal antibodies against interleukin 8 (IL-8)
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
US20100260739A1 (en) * 2009-03-09 2010-10-14 Bioatla, Llc Mirac Proteins
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
CN105521489A (zh) * 2014-09-28 2016-04-27 徐州逸仕生物技术有限公司 抗人TNF-αIgY抗体及其治疗皮肤疾病的应用
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3541358A1 (de) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermale verabreichung von grossen wirkstoffen
MX2020006171A (es) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
US5707621A (en) * 1994-08-31 1998-01-13 Chugai Pharmaceutical Co., Ltd. Supression of nephritis-induced protein excretion by anti-IL-8
JPH08277299A (ja) * 1995-04-06 1996-10-22 Fujirebio Inc 抗ｉｌ−８抗体、抗ｉｌ−８モノクローナル抗体を産生するハイブリドーマ及び該抗体を用いたｉｌ−８の測定方法
EP1878748A2 (de) * 1996-11-08 2008-01-16 Biogen Idec Inc. Identifikation der Wechselwirkungen einzelner Bindungen zwischen gewissen Antikörpern und humanen kostimulierenden B7.1- und B7.2-Antigenen

Also Published As

Publication number Publication date
CN1203105A (zh) 1998-12-30
DE69801660D1 (de) 2001-10-18
AU8096298A (en) 1999-01-04
CN1068524C (zh) 2001-07-18
WO1998058671A1 (en) 1998-12-30
AU727937B2 (en) 2001-01-04
CA2291144A1 (en) 1998-12-30
DE69801660T2 (de) 2002-06-06
US20030077283A1 (en) 2003-04-24
EP0991423A1 (de) 2000-04-12
CA2291144C (en) 2001-07-03
ES2164434T3 (es) 2002-02-16
EP0991423B1 (de) 2001-09-12

Similar Documents

Publication Publication Date Title
DE69801660D1 (de) Lokale behandlung von psoriasis unter verwendung neutralisierender antikörper gegen il-8
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
EP0669836A1 (de) Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma.
DE69940975D1 (de) Verwendung von glp-1 oder analoge zur behandlung von schlaganfall
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ES2124702T3 (es) Usos terapeuticos de compuestos que se unen a actina.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
BR9305783A (pt) Processo para preparar grânulos dispersiveis em água e grânulos dispersíveis em água
NO995843L (no) Farmasoeytisk preparat omfattende vWF-propeptid
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE69132575D1 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
AP9801416A0 (en) Method Of treating a plant disease.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties